Prediction of the disease burden of nasopharyngeal carcinoma in China: A comparative analysis of ARIMA, LSTM, and DNN models

中国鼻咽癌疾病负担预测:ARIMA、LSTM 和 DNN 模型的比较分析

阅读:1

Abstract

Nasopharyngeal carcinoma (NPC), highly prevalent in southern China, often presents insidious early symptoms, resulting in advanced-stage diagnosis, significant treatment challenges, and poor prognosis. Accurate prediction of NPC's disease burden is essential for devising effective prevention and treatment strategies and optimizing medical resource allocation. This study used the 2021 Global Burden of Disease (GBD) study's disability-adjusted life years (DALYs) data on NPC in China. It developed 3 disease burden prediction models (ARIMA, deep neural networks [DNN], and long short-term memory [LSTM]), whose performance was assessed by mean absolute error, mean absolute percentage error, and RMSE. The DNN model demonstrated superior fitting on the training set with the lowest error metrics, yet it exhibited overfitting as its performance declined on the testing set. In contrast, the ARIMA model, with its assumption of stationarity, achieved the best generalization with the lowest mean absolute error and mean absolute percentage error on the testing data. The LSTM model recorded higher errors on the test set. Forecasts for 2022 to 2030 showed that while ARIMA predicted stable DALYs, both DNN and LSTM models indicated a gradual decline. The future predictions of all 3 models indicate that although the disease burden of NPC may gradually decrease, it remains extremely severe. This study compared ARIMA, DNN, and LSTM models for predicting NPC disease burden in China. Although DNN excelled on training data, ARIMA generalized best on testing, while LSTM struggled due to limited data. Future research should integrate diverse sources and improve interpretability to support NPC prevention and treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。